Bye bye Ozempic: Eli Lilly says its new drug retatrutide more than doubles weight loss
Eli Lilly reports that its experimental weekly injection retatrutide more than doubles the weight loss of Novo Nordisk's Ozempic at its highest approved dose. Results from a phase 3 head-to-head diabetes showdown show the next-generation medication also delivered superior blood sugar reduction, measured by A1C levels. Retatrutide is often called a triple-G drug because it mimics three hunger-regulating hormones. Eli Lilly anticipates filing a regulatory application for the drug in the first quarter of 2027.
Listen to Live Briefing
Real-time synthesized voice briefing · Live Feeds Desk
- ✓ Eli Lilly's retatrutide delivered more than double the weight loss of Ozempic's highest approved dose in a head-to-head trial.
- ✓ Retatrutide also achieved greater A1C reduction compared to Ozempic.
- ✓ Retatrutide is a weekly injection that mimics three hunger-regulating hormones.
- ✓ Eli Lilly expects to submit a regulatory application for retatrutide in the first quarter of 2027.
What changed
Eli Lilly released phase 3 head-to-head trial data showing retatrutide outperforms Ozempic in weight loss and blood sugar reduction.
Live updates
-
Eli Lilly Says Retatrutide Beats Ozempic in Trial
Eli Lilly reports that its experimental weekly injection retatrutide more than doubles the weight loss of Novo Nordisk's Ozempic at its highest approved dose. Results from a phase 3 head-to-head diabetes showdown show the next-generation medication also delivered superior blood sugar reduction, measured by A1C levels. Retatrutide is often called a triple-G drug because it mimics three hunger-regulating hormones. Eli Lilly anticipates filing a regulatory application for the drug in the first quarter of 2027.
Why it matters
The trial results strengthen Eli Lilly's competitive position in the lucrative market for metabolic and weight loss treatments. Retatrutide follows the commercial success of the company's existing products, Mounjaro and Zepbound. Novo Nordisk's Ozempic has been a dominant therapy for type 2 diabetes and weight management.
What is confirmed
- Eli Lilly's retatrutide delivered more than double the weight loss of Ozempic's highest approved dose in a head-to-head trial.
- Retatrutide also achieved greater A1C reduction compared to Ozempic.
- Retatrutide is a weekly injection that mimics three hunger-regulating hormones.
- Eli Lilly expects to submit a regulatory application for retatrutide in the first quarter of 2027.
What to watch next
- Eli Lilly's official regulatory filing for retatrutide in the first quarter of 2027.
- Additional data releases from the phase 3 diabetes trial program.
confidence 100%Sources used for this update (12)
- www.yahoo.com — Yahoo
- Business Insider — Bye bye Ozempic: Eli Lilly says its new drug retatrutide more than doubles weight loss
- ABC News - Breaking News, Latest News and Videos — New weight loss drug retatrutide provides double the weight loss of Ozempic, Lilly says
- Reuters — Lilly's retatrutide outshines Ozempic on weight loss, blood sugar control in trial
- Eli Lilly — Lilly's retatrutide delivered greater A1C reduction and more than double the weight loss of Ozempic's highest approved dose in head-to-head trial
- STAT — Lilly says ‘triple-G’ drug beats Novo’s Ozempic in diabetes study
- STAT — Lilly’s triple-G drug beats Ozempic in head-to-head study
- Fierce Biotech — Lilly’s retatrutide bests Ozempic on blood sugar, weight loss in phase 3 diabetes showdown
- www.biospace.com — Lilly’s retatrutide trounces Novo’s Ozempic in diabetes ...
- abcnews.com — Retatrutide provides double the weight loss of Ozempic, data ...
- www.yahoo.com — Bye bye Ozempic: Eli Lilly says its new drug retatrutide more ...
- www.livemint.com — Ozempic vs Retatrutide: Eli Lilly claims 'more than double ...
Community Sentiment: How do you assess this situation?
Voice your perspective · Real-time aggregated sentiment from the Live Feeds community